Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Revolution Medicines, Inc.
Study ID
NCT06162221
Phase
PHASE1/PHASE2
Status
Recruiting

Conditions

  • KRAS G12C-mutated Solid Tumors, Lung Cancer
  • KRAS, NRAS, HRAS-mutated NSCLC
  • Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
  • Non-Small Cell Lung Cancer, NSCLC
  • RAS G12D-mutated NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RMC-6291 — DRUG
    Oral tablet
  • RMC-6236 — DRUG
    Oral tablet
  • Pembrolizumab — DRUG
    IV Infusion
  • Cisplatin — DRUG
    IV Infusion
  • Carboplatin — DRUG
    IV Infusion
  • Pemetrexed — DRUG
    IV infusion
  • RMC-9805 — DRUG
    Oral Tablet

Study Details

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Key Dates

First listed
Dec 8, 2023
Start date
Jan 18, 2024
Status verified
Jun 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
616 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Subprotocol A: KRAS G12C-Mutated Solid Tumors
    RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)
  • Experimental: Subprotocol B: RAS-mutated NSCLC
    RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)
  • Experimental: Subprotocol C: RAS G12D-mutated NSCLC
    RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W).
  • Experimental: Subprotocol D: RAS G12D-mutated NSCLC
    RMC-9805 (QD)

Primary Outcome Measure

Adverse events [ Time Frame: Up to 5 years ]

Central Contacts

Locations (28)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer CenterGilbertArizona85234-
City of Hope - DuarteDuarteCalifornia91010
Taylor Alexander
877-467-3411
City of Hope - LennarIrvineCalifornia92618
Stephanie Casal
866-442-9785
UC Davis, Davis Comprehensive Cancer CenterSacramentoCalifornia95817
Thanina Amirat
916-734-3186
University of California, San Diego Moores Cancer CenterSan DiegoCalifornia92037
Kathy Velasco
858-822-5677
UCSF Medical Center - Mission BaySan FranciscoCalifornia94158
415-866-7866
Stanford University - Stanford Cancer InstituteStanfordCalifornia94305
650-498-6000
Colorado Health Medical Group - Medical Oncology & HematologyColorado SpringsColorado80909-
Georgetown University Medical CenterWashington D.C.District of Columbia20007
Shannon Raue
202-784-5097
Boca Raton Clinical Research AssociatesPlantationFlorida33322
Sandra Perez
561-447-0614
Cancer Specialists of North FloridaSaint AugustineFlorida32086
Justin Elkins
904-538-4488
H Lee Moffitt Cancer Center and Research InstituteTampaFlorida33612
Ana Aminpour
813-745-0287
Dana Farber Cancer InstituteBostonMassachusetts02215
Thoracic KRAS Referrals
877-442-3324
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)DetroitMichigan48202
Dalia Abdullah
313-874-7518
Intermountain Health - St. Vincent Frontier Cancer CenterBillingsMontana59102
Heather Duyck
406-238-6290
Nebraska Cancer SpecialistGrand IslandNebraska68803-
Columbia University Medical CenterNew YorkNew York10032
212-342-5162
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Jessica Setal-Hunte
212-241-2293
New York University Langone HealthNew YorkNew York10016
Salman Punekar
212-731-6228
Clinical Research AllianceWestburyNew York11590
516-488-2918
University Hospitals Cleveland Medical CenterClevelandOhio44106
216-844-3951
UPMC Hillman Cancer CenterPittsburghPennsylvania15232
Baptist Medical CenterMemphisTennessee38120-
Tennessee OncologyNashvilleTennessee37203-
The University of Texas MD Anderson Cancer CenterHoustonTexas77030
Alison Shaw
713-563-1235
NEXT Oncology DallasIrvingTexas75039
Idara Ukpong
972-893-8800
NEXT Oncology VirginiaFairfaxVirginia22031
Blake Patterson
703-783-4505
Fred Hutchinson Cancer Research CenterSeattleWashington98109-

Find similar trials in Gilbert, AZ